The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases.

The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases.

Bibliographic Details
Main Author:	Michael J Brennan
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2009-07-01
Series:	PLoS Medicine
Online Access:	http://europepmc.org/articles/PMC2705496?pdf=render

Similar Items

Vaccines, Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food and Drug Administration
by: Kathryn C. Zoon
Published: (1999-08-01)

Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis
by: Matthew J Jackson, et al.
Published: (2024-03-01)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.
by: Robert K M Choy, et al.
Published: (2020-07-01)

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
by: Enrique Seoane-Vazquez, et al.
Published: (2024-02-01)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.
by: Helen W Sullivan, et al.
Published: (2016-01-01)

A U.S. Food and Drug Administration perspective on cannabis research and drug development
by: Cassandra L. Taylor, et al.
Published: (2023-10-01)

Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)
by: White, NJ, et al.
Published: (2022)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
by: Joe Lex
Published: (2016-11-01)

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
by: Zineh Issam, et al.
Published: (2010-04-01)

Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection
by: M. V. Savkina, et al.
Published: (2021-12-01)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
by: Carrie M. Kuehn
Published: (2019-08-01)

Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.
by: Stanton A Glantz, et al.
Published: (2009-07-01)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
by: Fei Liang, et al.
Published: (2020-08-01)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
by: Nadia Zuabi, et al.
Published: (2016-11-01)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
by: Gelareh A. Abulwerdi, et al.
Published: (2023-10-01)

Administrative and legal regulation of licensing for medical practice
by: О. V. Batryn
Published: (2024-03-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)

Psychosocial services provided by licensed cardiac rehabilitation programs
by: Montika Bush, et al.
Published: (2023-03-01)

Inventions in the marketplace : patent licensing and the U.S. antitrust laws /
by: Hoff, Paul S., 1942-
Published: (c198)

Vaccines licensed and in clinical trials for the prevention of dengue
by: J. Torresi, et al.
Published: (2017-05-01)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
by: Joshua D. Wallach, et al.
Published: (2019-06-01)

Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
by: Marwan N. Sabbagh, et al.
Published: (2023-01-01)

Supporting US healthcare providers for successful vaccine communication
by: Amanda J Pierz, et al.
Published: (2023-05-01)

Endovascular Strategies for Aortic Arch When US Food and Drug Administration–Approved Devices Are Not Available
by: Gabrielle Sutton, MS, et al.
Published: (2024-03-01)

US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer
by: Stacy S. Shord, et al.
Published: (2023-11-01)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
by: Ying Zhang, et al.
Published: (2023-07-01)

Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration Animal rule
by: Chia-Wei eTsai, et al.
Published: (2015-12-01)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
by: Min Fan, et al.
Published: (2022-01-01)

Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design.
by: Natsuko Imai, et al.
Published: (2018-01-01)

Vaccine politics : compulsory licensing in SE Asia?
by: Sworn, Hannah Elyse
Published: (2021)

Tracking the presence of software as a medical device in US Food and Drug Administration databases: Retrospective data analysis
by: Ceross, A, et al.
Published: (2021)

Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration
by: Michelle B. Nadler, et al.
Published: (2024-01-01)

Current Status of Administrative Licensing for Laboratory Animals in Jiangsu Province
by: CHEN Lin, et al.
Published: (2021-08-01)

The Current Status of Laboratory Animal License Administration in Guangdong Province
by: LI Huiping, et al.
Published: (2022-12-01)

US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
by: Haidar Al Saffar, et al.
Published: (2023-06-01)

The global crisis, government contracts, licensing and corruption
by: Halil D. Kaya
Published: (2023-12-01)

An Open Access Database of Licensed Cancer Drugs
by: Pan Pantziarka, et al.
Published: (2021-03-01)

The Delay in the Licensing of Protozoal Vaccines: A Comparative History
by: Clarisa Beatriz Palatnik-de-Sousa, et al.
Published: (2020-03-01)

Licensing by modification Licensing by modification
by: Veneeta Dayal
Published: (2008-04-01)